Skip to main content
National News Desk
health

Gilead signs generic licensing deals for experimental Ebola drug

The Hindu Health & MedicalBy The Hindu Health & Medical
18 Nov 2026
Original: English
AI Synopsis & Key Briefing

A late-stage trial is testing the drug in people at high risk after exposure. The deals are intended to line up manufacturing and supply before trial results and regulatory filings

Key Highlights & Official Takeaways
  • ✓A late-stage trial is testing the drug in people at high risk after exposure.
  • ✓The deals are intended to line up manufacturing and supply before trial results and regulatory filings
  • ✓Civic Domain: Categorized under health public notices.
Comprehensive News & Policy Report

Gilead Sciences said on Monday it had signed royalty-free deals with three generic drugmakers to make its experimental Ebola prevention drug available in 127 mainly low- and lower-middle-income countries if it succeeds in trials and wins regulatory approvals.

The deals with Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories cover obeldesivir, and include all African countries reporting cases in the current Ebola Bundibugyo outbreak. Obeldesivir has shown activity against several Ebola-related viruses in preclinical studies but is not approved for any use in any country.

A late-stage trial is testing the drug in people at high risk after exposure. The deals are intended to line up manufacturing and supply before trial results and regulatory filings. Gilead is also expanding remdesivir licences to cover Ebola-related diseases if trial results are positive and regulators approve the drug.

The company has donated more than 38,000 remdesivir vials to the Democratic Republic of Congo, Uganda and Kenya, including more than 2,000 recently sent to Kenya for investigational treatment and post-exposure prevention.

Remdesivir is not approved to treat or prevent Ebola Bundibugyo disease, and its clinical effectiveness has not been established.

Actionable Steps for Aspirants & Citizens
  • •Aspirants and citizens are advised to monitor official notices and circulars issued by The Hindu Health & Medical.
  • •Verify all prescribed eligibility criteria, cutoff dates, and authenticated document requirements prior to formal submissions.
  • •Track connected examination timetables, vacancy advisories, and administrative gazettes on SuchnaSetu.
Official Notice Specification
Issuing AuthorityThe Hindu Health & Medical
Topic CategoryHEALTH
JurisdictionAll India / National
Publication Date18 November 2026
Connected Government Jobs & Upcoming Exams
Active on SuchnaSetu
Official Source Attribution: The Hindu Health & Medical
View Publisher Source Link

SuchnaSetu provides verified civic and public policy reports based on official notices. Primary publication and copyright remain with the respective government authority or publisher.